MidMarketNow
Get the Weekly

Centauri Therapeutics

—

SectorsHealthcare2
Regions—
Last activity

Activity, last 12 months

Centauri Therapeutics — events per month, last 12 months
Centauri Therapeutics — events per month, last 12 months
MonthEvents
August 20250
September 20250
October 20250
November 20250
December 20250
January 20260
February 20262
March 20260
April 20260
May 20260
June 20260
July 20260

Deal history

  1. Centauri extends Series A to £30M with AMR Action Fund

    Centauri Therapeutics has extended its Series A to £30M, including a £6M investment from the AMR Action Fund, to support Phase I progress for lead candidate CTX-187.

  2. AMR Action Fund backs Centauri with EUR 23.62m

    Centauri Therapeutics has announced a EUR 23.62 million funding from the AMR Action Fund to advance its Alphamer-based “programmable immunity” approach targeting antimicrobial resistance.

We use privacy-respecting product analytics to understand how readers use MidMarketNow and improve it. No personal data (email, IP) is sent. See our privacy policy.